We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction to Cancer Therapy
-
1. Early detection of lung cancer
- Prof. Stephen Lam
-
2. Development of a cancer drug
- Prof. Martin Edelman
- Use of Novel "Targeted" Agents in Combination with Classical Cytotoxic Chemotherapy
-
3. Cytotoxic chemotherapy
- Dr. Michael Sawyer
-
4. Small molecule inhibitors of receptor tyrosine kinases
- Dr. Daniela Krause
- Innovative Strategies of Clinical Drug Development
-
5. Phase II trials
- Dr. Patricia Tang
-
6. Surrogate endpoints of efficacy
- Prof. Maurie Markman
- Biomarkers in Oncology: Rationale Development and Current Use
-
7. Biomarkers in oncology: overview
- Prof. Joe Duffy
- Archived Lectures *These may not cover the latest advances in the field
-
9. Emerging trends in phase II trial design
- Dr. Patricia Tang
-
11. Therapy in cancer 2008: quo vadis?
- Dr. Jeffrey Clark
-
13. Phase III trials
- Prof. Martin Edelman
-
15. Gene profiling in breast cancer
- Dr. Enrique Espinosa
-
18. Understanding cancer trends
- Prof. Michael Thun
-
20. Phase I study design for non-cytotoxic agents
- Dr. Wendy Parulekar
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Why are new therapeutic approaches important
- Prevention and screening
- Current cancer therapy: non-surgical
- Most chemotherapy targets DNA
- Chemotherapy effects
- Current state of cancer therapy: Efficacy
- Current state of cancer therapy: Toxicity
- Molecular pathogenesis of cancer
- Pursuing targeted therapy in cancers
- Targeted biologic therapies
- Potential targets in cancer
- Evolving targets and agents
- Shift from chemotherapy to targeted agents
- Clinically established molecular targets
- Targeted therapy: proteins
- Targeted therapy: small molecules
- Changes brought about by targeting: Efficacy
- Changes brought about by targeting: Toxicity
- Biomarkers in drug development (1)
- What is currently known (Biomarkers)
- What research is ongoing (Biomarkers)?
- Example for the use of biomarkers
- What is currently known (Angiogenesis)?
- The VEGF family and its receptors
- VEGF targeted therapy
- Phase 3 trial of bevacizumab in MCRC: Survival
- Biological correlates of bevacizumab
- Does toxicity correlate with response?
- Metastatic CRC
- What research is ongoing (Agents)?
- Sorafenib
- Phase I of sorafenib (DF/HCC, USC)
- Phase I's of sorafenib (pooled)
- Does toxicity correlate with time to progression?
- Phase III trial RCC
- Future directions in cancer treatment options
- Sequencing: same pathways, different mutations
- Core pathways altered in pancreatic cancer
- Core pathways altered in colorectal cancer
- Implications of genetic sequencing of solid tumors
- Pancreatic cancers sequencing
- Epigenetics and cancer therapy
- Conclusions
- Closing remarks
Topics Covered
- Why pursuing new therapeutic approaches in cancer is important
- Prevention and screening
- Current cancer therapy: non-surgical
- Most chemotherapy targets DNA
- Chemotherapy effects
- Current state of cancer therapy: efficacy and toxicity
- Molecular pathogenesis of cancer
- Pursuing targeted therapy in cancers
- Targeted biologic therapies
- Evolving targets and agents
- Shift from chemotherapy to targeted agents
- Clinically established molecular targets in malignancies
- Targeted therapy: proteins and small molecules
- Changes brought about by targeting: efficacy and toxicity
- Biomarkers in drug development
- What is currently known: angiogenesis
- The VEGF family and its receptors
- Bevacizumab and Sorafenib
- Does toxicity correlate with response?
- What research is ongoing: agents?
- Future directions in cancer treatment options
- Core pathways altered in pancreatic and colorectal cancer
- Implications of genetic sequencing of solid tumors to date
- Epigenetics and cancer therapy
Talk Citation
Clark, J. (2009, January 6). Therapy in cancer 2008: quo vadis? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 23, 2024, from https://hstalks.com/bs/1112/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jeffrey Clark has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.